Item Type | Name |
Academic Article
|
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
|
Concept
|
Thiazoles
|
Academic Article
|
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
|
Academic Article
|
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
|
Academic Article
|
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
|
Academic Article
|
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
|
Academic Article
|
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.
|
Academic Article
|
Dasatinib for the treatment of chronic myeloid leukemia.
|
Academic Article
|
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
|
Academic Article
|
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
|
Academic Article
|
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
|
Academic Article
|
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
|
Academic Article
|
Dasatinib.
|
Academic Article
|
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
|
Academic Article
|
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
|
Academic Article
|
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
|
Academic Article
|
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
|
Academic Article
|
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
|
Academic Article
|
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
|
Academic Article
|
Treatment selection after imatinib resistance in chronic myeloid leukemia.
|
Academic Article
|
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
|
Academic Article
|
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
|
Academic Article
|
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
|
Academic Article
|
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
|
Academic Article
|
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
|
Academic Article
|
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
|
Academic Article
|
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
|
Academic Article
|
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
|
Academic Article
|
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
|
Academic Article
|
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
|
Academic Article
|
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
|
Academic Article
|
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
|
Academic Article
|
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
|
Academic Article
|
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
|
Academic Article
|
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
|
Academic Article
|
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
|
Academic Article
|
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
|
Academic Article
|
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
|
Academic Article
|
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
|
Academic Article
|
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
|
Academic Article
|
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
|
Academic Article
|
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
|
Academic Article
|
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
|
Academic Article
|
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
|
Academic Article
|
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
|
Academic Article
|
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
|
Academic Article
|
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
|
Academic Article
|
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
|
Academic Article
|
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
|
Academic Article
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
Academic Article
|
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
|
Academic Article
|
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
|
Academic Article
|
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
|
Academic Article
|
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
|
Academic Article
|
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
|
Academic Article
|
First-line therapy for chronic myeloid leukemia: Past, present, and future.
|
Academic Article
|
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
|
Academic Article
|
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
|
Academic Article
|
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
|
Academic Article
|
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
|
Academic Article
|
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
|
Academic Article
|
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
|
Academic Article
|
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
|
Academic Article
|
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
|
Academic Article
|
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
|
Academic Article
|
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
|
Academic Article
|
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
|
Academic Article
|
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
|
Academic Article
|
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
|
Academic Article
|
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
|
Academic Article
|
Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
|
Academic Article
|
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
|
Academic Article
|
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
|
Academic Article
|
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
|
Academic Article
|
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
|
Academic Article
|
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
|
Academic Article
|
Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia.
|